Potent bromodomain and extraterminal domain inhibitor JAB-8263 suppresses MYC expression and exerts anti-tumor activity in colorectal cancer models

Figure 4 JAB-8263 suppressed tumor growth in colorectal cancer murine xenograft models. A and E: The SW837 xenograft model (6 mice for each group) was treated with JAB-8263 0.3 mg/kg for 29 d. The average tumor volume was significantly decreased compared to the vehicle control group, P < 0.001; B: There was no significant difference in body weight change between groups; C and F: The MC38 syngeneic murine model (8 mice for each group) was treated with JAB-8263 0.2 mg/kg for 29 d. The average tumor volume was significantly decreased compared to the vehicle control group, P = 0.003; D: There was no significant difference in body weight change between groups; G and H: The tumor tissue of the MC38 syngeneic murine model (3 mice for each group) after a single dose of JAB-8263 treatment was collected for the Western blotting assay. Compared with the control group, the expression of c-MYC in the treatment group was downregulated, ^aP < 0.05.